Incidence of Use of High-Flow Nasal Cannula Oxygen Therapy in Intensive Care Units Patients

NCT04141956 | Completed

• 1 other identifier: RC19_0386
• Study Type: observational
• Target: 257
• Locations: 1 country
• Sites: 10

Brief Summary

Patients with one or more organ failure (heart, lung) require hospitalization in intensive care where these failures can be managed. Nearly 30% of patients in intensive care units are hospitalized for acute respiratory distress (lung failure). This failure occurs in about 20% of postoperative patient, but it can also occur in the context of a pathology specific to the lung or after weaning of mechanical ventilation. It is therefore interesting to develop several techniques to provide oxygen to these patients with the aim in particular to avoid the use of intubation (insertion of a tube into the trachea to achieve artificial ventilation). For the past ten years, High-Flow Nasal Canula (HFNC) has developed. This technique reduces the need for intubation but the studies are contradictory, however they agree on its ease of use and the few risks associated with it. The principle of this technique is to deliver a humidified and heated gas mixture at a high rate through large nasal cannula. The advantage of this device is its non-invasive and the possibility of administering a large amount of oxygen. There is a certain craze for this oxygenation technique despite few scientific studies in the literature. However, it requires the expertise of the medical and paramedical team so as not to delay intubation. The investigators propose to carry out an observational study (without any modification of the usual practices) with epidemiological aim in order to make an inventory of the modes of use of the HFNC, in particular on its frequency of use and on its duration of use per patient hospitalized in intensive care. The investigators will recruit all HFNC patients in intensive care units (20 centers) (30 patients / center): 15 after weaning of mechanical ventilation and 15 others for other reasons. Patients will be followed every day and up to 48 hours after removal of the HFNC.

Conditions

Oxygen Deficiency

Outcome Measures

Primary Outcomes (1)

• Incidence of nasal High-Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care

  Incidence defined by: the ratio of the number of patients under HFNC on the number of patients admitted to intensive care during the period of inclusion.

  28 days after enrollment

Interventions

High-Flow Nasal Cannula OTHER

Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All adults' patients, admitted to intensive care units treated with HFNC (indication is to discretion of doctor). For example : Acute Hypoxemic Respiratory Failure, Postoperative Respiratory Failure or systematic when weaning mechanical ventilation.

You may qualify if:

• all adults' patients, admitted to intensive care units treated with HFNC (indication is to discretion of doctor).

You may not qualify if:

• HFNC use for Preoxygenation and Apneic Oxygenation for Intubation

Sponsors & Collaborators

• Nantes University Hospital: lead

Study Sites (10)

Chu Jean Minjoz Besancon

Besançon, 25030, France

Location

CHU CAEN

Caen, 14033, France

Location

Polyclinique Du Cotentin

Cherbourg, 50100, France

Location

Centre Hospitalier Du Mans

Le Mans, 72037, France

Location

CHU de Nantes

Nantes, France

Location

Chru Orleans

Orléans, 45067, France

Location

CH de SAINT NAZAIRE

Saint-Nazaire, 44606, France

Location

Hopital Foch

Suresnes, 92150, France

Location

Chru Bretonneau - Tours

Tours, 37044, France

Location

Centre Hospitalier Bretagne-Atlantique -Site de Vannes

Vannes, 56017, France

Location

MeSH Terms

Conditions

Hypoxia

Condition Hierarchy (Ancestors)

Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 25, 2019
• First Posted: October 28, 2019
• Study Start: November 2, 2019
• Primary Completion: October 30, 2020
• Study Completion: October 30, 2020
• Last Updated: March 17, 2025

Record last verified: 2025-03

Locations

FR (10)